KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $1.6 billion.

  • Gilead Sciences' Cost of Revenue fell 31.77% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 billion, marking a year-over-year decrease of 841.72%. This contributed to the annual value of $6.3 billion for FY2024, which is 380.12% down from last year.
  • Latest data reveals that Gilead Sciences reported Cost of Revenue of $1.6 billion as of Q3 2025, which was down 31.77% from $1.5 billion recorded in Q2 2025.
  • In the past 5 years, Gilead Sciences' Cost of Revenue registered a high of $2.6 billion during Q4 2021, and its lowest value of $1.2 billion during Q3 2021.
  • Its 5-year average for Cost of Revenue is $1.6 billion, with a median of $1.5 billion in 2025.
  • In the last 5 years, Gilead Sciences' Cost of Revenue soared by 8791.13% in 2021 and then tumbled by 4685.95% in 2022.
  • Over the past 5 years, Gilead Sciences' Cost of Revenue (Quarter) stood at $2.6 billion in 2021, then crashed by 46.86% to $1.4 billion in 2022, then skyrocketed by 49.71% to $2.1 billion in 2023, then fell by 24.35% to $1.6 billion in 2024, then dropped by 0.76% to $1.6 billion in 2025.
  • Its Cost of Revenue was $1.6 billion in Q3 2025, compared to $1.5 billion in Q2 2025 and $1.5 billion in Q1 2025.